Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo

Author: Epeius Biotechnologies Corporation
Dateline: Tue, 25 Mar 2008

freeNewsArticles Story Summary: “SAN MARINO, Calif., March 25 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent, Rexin-G.”



A R T I C L E:

SAN MARINO, Calif., March 25 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company’s leading anti-cancer agent, Rexin-G. Administered clinically by simple intravenous infusion, the Epeius tumor-targeted gene delivery system enables Rexin-G to seek out and accumulate selectively in cancerous tissues and remote metastatic tumor nodules that have spread throughout the body. Rexin-G delivers it tumor-killing payload precisely where it is needed most, by targeting cancer from the inside.

EpeiusRexin-G demonstrates profound single agent efficacy in a broad spectrum of chemotherapy refractory cancers, including pancreatic cancer, breast cancer, colon cancer, squamous cell carcinoma of larynx, uterine cancer, gastric cancer, malignant melanoma, validating Epeius Biotechnologies’ in vivo targeted gene delivery platform (Int’l J Oncol, 2006, 2007).

The response rates seen with Rexin-G are unmatched by any other tumor-targeted gene delivery system. The U.S. FDA has granted Orphan Drug Status to Rexin-G based on its performance as a single therapeutic agent in treating chemotherapy refractory pancreatic cancer. Based on its exemplary record of safety and efficacy as an anti-cancer agent in a broad spectrum of chemo-resistant tumors, Rexin-G received accelerated approval for the treatment of all solid tumors by the Philippine BFAD, leading to its registration.

Currently, Rexin-G is being tested as a single therapeutic agent in three separate U.S. Phase I/II Trials for recurrent or metastatic cancers of the breast or pancreas and for bone and soft tissue sarcoma respectively. Additionally, a Phase II Registration Protocol is underway for chemo-resistant osteosarcoma in Los Angeles, California.

About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems.

Credited with innovations ranging from proto-oncogene discovery, designer therapeutics, pathotropic (disease-seeking) targeting, high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to “launch” its enabling platform technologies for the benefit of cancer patients worldwide.

To learn more about Rexin-G(R) and the Epeius pipeline of proprietary biotechnologies currently available for licensing and clinical trials, please visit us at www.epeiusbiotech.com.


###


Copyright © 2008 by Epeius Biotechnologies Corporation and Send2Press® Newswire, a service of Neotrope® – all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.

Story Title: Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
• REFERENCE KEYWORDS/TERMS: Epeius Biotechnologies RexinG, , , biopharmaceutical cancer research, Drugs and Pharmaceuticals, , , .

IMPORTANT NOTICE: some content which is considered “old” or “archival” may reference an event which has already occurred; some content possibly considered “advertorial” may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (Epeius Biotechnologies Corporation); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Tue, 25 Mar 2008 01:05:29 GMT].

USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.

Posted

in

by